A detailed history of Handelsbanken Fonder Ab transactions in Insmed Inc stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 43,581 shares of INSM stock, worth $3.22 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
43,581
Previous 34,781 25.3%
Holding current value
$3.22 Million
Previous $2.33 Million 36.52%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$62.0 - $79.01 $545,600 - $695,288
8,800 Added 25.3%
43,581 $3.18 Million
Q2 2024

Aug 05, 2024

BUY
$22.0 - $69.71 $94,600 - $299,753
4,300 Added 14.11%
34,781 $2.33 Million
Q1 2024

May 13, 2024

BUY
$25.72 - $29.94 $48,868 - $56,886
1,900 Added 6.65%
30,481 $827,000
Q4 2023

Feb 01, 2024

BUY
$23.42 - $31.74 $16,394 - $22,218
700 Added 2.51%
28,581 $886,000
Q2 2023

Aug 02, 2023

SELL
$16.44 - $21.1 $24,660 - $31,650
-1,500 Reduced 5.11%
27,881 $588,000
Q1 2023

Apr 28, 2023

BUY
$16.26 - $21.73 $182,112 - $243,376
11,200 Added 61.6%
29,381 $501,000
Q4 2022

Feb 07, 2023

BUY
$16.98 - $23.15 $57,732 - $78,710
3,400 Added 23.0%
18,181 $363,000
Q3 2022

Oct 27, 2022

SELL
$20.88 - $28.21 $83,520 - $112,840
-4,000 Reduced 21.3%
14,781 $318,000
Q1 2022

May 11, 2022

SELL
$20.42 - $28.13 $104,142 - $143,463
-5,100 Reduced 21.36%
18,781 $441,000
Q2 2021

Aug 03, 2021

BUY
$24.17 - $36.01 $108,765 - $162,045
4,500 Added 23.22%
23,881 $680,000
Q3 2020

Nov 13, 2020

BUY
$26.0 - $34.5 $187,200 - $248,400
7,200 Added 59.11%
19,381 $623,000
Q2 2020

Aug 13, 2020

BUY
$14.11 - $29.42 $171,873 - $358,365
12,181 New
12,181 $335,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.